Hormone replacement therapy on ovarian and uterine cancer risk and cancer survivors: how shall we do no harm?

V Loizzi, G Cormio, M Vicino, N Fattizzi, S Bettocchi, L Selvaggi
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2005 · doi:10.1111/j.1525-1438.2005.15303.x · PMID:15882164
review OA: closed public-domain-us
View on PubMed View at publisher

Abstract

This article will focus on the results of the Women's Health Initiative on the effects of hormone replacement therapy on coronary heart disease, stroke, venous thromboembolism, breast cancer, and colorectal cancer. Data from other relevant trials, including the most recent data on ovarian and uterine cancer risk and on gynecologic cancer patients, are also discussed to provide some guidelines on prescribing hormone replacement therapy in clinical practice, particularly in gynecologic cancer survivors.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Hormone Replacement Therapy Ovarian Neoplasms Survivors Uterine Neoplasms Breast Neoplasms Breast Neoplasms Colorectal Neoplasms Colorectal Neoplasms Endometriosis Female Heart Diseases Heart Diseases Hormone Replacement Therapy Humans Ovarian Neoplasms Randomized Controlled Trials as Topic Risk Factors Thromboembolism Thromboembolism Uterine Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
pubmed
last seen: 2026-05-13T22:15:41.664291+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine